Homeopathy 2015; 104(01): 48-56
DOI: 10.1016/j.homp.2014.05.007
Original Paper
Copyright © The Faculty of Homeopathy 2014

Trypanosoma cruzi: Biotherapy made from trypomastigote modulates the inflammatory response

Patrícia Sandri
1   Universidade Estadual de Maringá, Departamento de Ciências Básicas da Saúde/Parasitologia, Maringá, PR, Brazil
,
Denise Lessa Aleixo
1   Universidade Estadual de Maringá, Departamento de Ciências Básicas da Saúde/Parasitologia, Maringá, PR, Brazil
,
Gislaine Janaina Sanchez Falkowski
1   Universidade Estadual de Maringá, Departamento de Ciências Básicas da Saúde/Parasitologia, Maringá, PR, Brazil
,
Anélio Dias Nascimento Júnior
2   Universidade Estadual de Maringá, Departamento de Farmácia, Maringá, PR, Brazil
,
Mônica Lúcia Gomes
1   Universidade Estadual de Maringá, Departamento de Ciências Básicas da Saúde/Parasitologia, Maringá, PR, Brazil
,
Luzmarina Hernandes
3   Universidade Estadual de Maringá, Departamento de Ciências Morfofisiológicas, Maringá, PR, Brazil
,
Márcia Machado de Oliveira Dalalio
4   Universidade Estadual de Maringá, Departamento de Ciências Básicas da Saúde/Imunologia, Maringá, PR, Brazil
,
Neide Martins Moreira
1   Universidade Estadual de Maringá, Departamento de Ciências Básicas da Saúde/Parasitologia, Maringá, PR, Brazil
,
Max Jean de Ornelas Toledo
1   Universidade Estadual de Maringá, Departamento de Ciências Básicas da Saúde/Parasitologia, Maringá, PR, Brazil
,
Maristela Gabriel
1   Universidade Estadual de Maringá, Departamento de Ciências Básicas da Saúde/Parasitologia, Maringá, PR, Brazil
,
Silvana Marques de Araújo
1   Universidade Estadual de Maringá, Departamento de Ciências Básicas da Saúde/Parasitologia, Maringá, PR, Brazil
› Institutsangaben

Verantwortlicher Herausgeber dieser Rubrik:
Weitere Informationen

Publikationsverlauf

Received19. November 2013
revised30. April 2014

accepted28. Mai 2014

Publikationsdatum:
23. Dezember 2017 (online)

This study evaluates the effect of Trypanosoma cruzi biotherapy 17dH (BIOT) on mice of different ages, infected with the protozoa concerned.

Method: Performing a blind, controlled, randomized by drawing experiment, 110 animals four or eight-week-old, Swiss, male mice were divided into infected control treated hydroalcoholic 7% (CI-4 = 34 or CI-8 = 21 animals) and infected control treated with biotherapy 17dH–0.2 mL/animal/20 consecutive days/oral regimen (BIOT-4 = 33 or BIOT-8 = 21 animals). Animals were inoculated intraperitoneally with 1400 trypomastigote, T. cruzi Y-strain. Parasitological, immunological and histopathologic parameters were evaluated statistically, using Statistica-8.0 and R 3.0.2 program to analysis of survival. The study was approved by the Ethics Committee for Animal Experimentation/UEM.

Results: Four-week-old mice showed no statistical difference in parasitemia (P = 0.5718) between the treated and control group. Eight-week-old mice from the treated group had a higher parasite peak (P = 0.0424) and higher parasitemia (P < 0.005) than the control. To both groups of 4 and 8 weeks of age, treated or untreated, survival of mice was higher in the treated group than in the control, although it was not statistically significant (p-value = 0.32, 0.55 respectively). Four-week-old mice displayed a spleen section with a number of amastigote nests significantly higher in BIOT-4 than CI-4 (P = 0.01). In eight-week-old mice the number of amastigote nests (P < 0.001) and inflammatory foci (P < 0.06–10% significance) in the liver section were smaller in BIOT-8 than CI-8. Spleen giant cells were significantly higher in CI-8 than in BIOT-8 (P < 0.01). Eight-week-old animals treated with biotherapy showed higher parasitemia and lower tissue parasitism. Opposite pattern was observed in four-week-old animals.

Conclusion: There is a difference of high diluted medication effect in four and eight-week-old mice. In the group of animals 8 weeks the immunomodulatory effect seems to have been higher. Hence, treatment with the medicine produced from T. cruzi modulates the inflammatory response with increased apoptosis and decreased serum levels of TGF-β.

 
  • References

  • 1 Nagajyothi F., Kuliawat R., Kusminski C.M. et al. Alterations in glucose homeostasis in a murine model of chagas disease. Am J Pathol 2013; 182 (03) 886-894.
  • 2 Tibayrenc M., Telleria J. American trypanosomiasis Chagas disease. In: De Lana M., Machado E.M.M. (eds). Biology of Trypanosoma cruzi and biological diversity Elsevier; London: 2010: 339-363 Chap. 14.
  • 3 Albuquerque D.A., Martins G.A., Campos-Neto A., Silva J.S. The adjuvant effect of jacalin on the mouse humoral immune response to trinitrophenyl and Trypanosoma cruzi . Immunol Lett 1999; 68 2–3 375-381.
  • 4 Cestari I., Evans-Osses I., Schlapbach L.J., Messias-Reason I., Ramirez M.I. Mechanisms of complement lectin pathway activation and resistance by trypanosomatid parasites. Mol Immunol 2013; 53 (04) 328-334.
  • 5 De Souza W. O parasito e sua interação com os hospedeiros. In: Brener Z., Andrade Z., Barral-Neto M. (eds). Trypanosoma cruzi e Doença de Chagas 2rd edn. Guanabara Koogan; Rio de Janeiro: 2000: p.88-126.
  • 6 Freire-de-Lima C.G., Nascimento D.O., Soares M.B. et al. Uptake of apoptotic cells drives the growth of a pathogenic trypanosome in macrophages. Nature 2000; 403 6766 199-203.
  • 7 Dos Reis G.A. Evasion of immune responses by Trypanosoma cruzi, the etiological agent of Chagas disease. Braz J Med Biol Res 2011; 44 (02) 84-90.
  • 8 Neres J., Bryce R.A., Douglas K.T. Rational drug design in parasitology:trans-sialidase as a case study for Chagas disease. Drug Discov Today 2008; 13 3–4 110-117.
  • 9 Bellavite P., Lussignoli S., Semizzi M.L., Ortolani R., Signorini A. The similia principle: From cellular models to regulation of homeostasis. Br Homoeopath J 1997; 86 (02) 73-85.
  • 10 Teixeira M.Z. Homeopatia nas doenças epidêmicas: conceitos, evidências e propostas. Rev Homeopat 2010; 73 1–2 36-56.
  • 11 Aleixo D.L., Ferraz F.N., Ferreira E.C. et al. Highly diluted medication reduces parasitemia and improves experimental infection evolution by Trypanosoma cruzi . BMC Res Notes 2012; 5: 32.
  • 12 Eisenberg D.M., Davis R.B., Ettner S.L. et al. Trends in alternative medicine use in the United States, 1990-1997. J Am Med Assoc 1998; 280 (18) 1569-1575.
  • 13 Ouaissi A., Ouaissi M., Tavares J., Cordeiro-Da-Silva A. Host cell phenotypic variability induced by Trypanosomatid parasite released immunomodulatory factors: physiopathological implications. J Biomed Biotechnol 2004; 3: 167-174.
  • 14 Almeida L.R., Campos M.C., Herrera H.M., Bonamin L.V., da Fonseca A.H. Effects of homeopathy in mice experimentally infected with Trypanosoma cruzi . Homeopathy 2008; 97 (02) 65-69.
  • 15 Queiroz A.O., Xavier S.C.C., Faria K.G., Bernardo R.R., Leitão T.C.A. Avaliação do bioterápico Trypanosoma cruzi 30 DH: Um Estudo In Vivo . Cult Homeopat 2006; 17: 9-13.
  • 16 Ferraz F.N., Simoni G.K., Nascimento A.D. et al. Different forms of administration of biotherapy 7dH in mice experimentally infected by Trypanosoma cruzi produce different effects. Homeopathy 2011; 100 (04) 237-243.
  • 17 Silva L.H.P., Nussenzweig V. Sobre uma cepa de Trypanosoma cruzi altamente virulenta para o camundongo branco. Folia Clin Biol Sao Paulo 1953; 20: 191-201.
  • 18 Farmacopéia homeopática Brasileira. 3a edição. Ministério da Saúde, 2011. Brasília. DF. Brasil.
  • 19 Saúde Ministério da. Dispõe sobre boas práticas de manipulação de preparações magistrais e oficinais para uso humano em farmácias. Resolução da Diretoria Colegiada - RDC no. 67, Diário Oficial da União, Brasília, DF. Brasil 2007
  • 20 Brener Z. Therapeutic activity and criterion of cure in mice experimentally infected with Trypanosoma cruzi . Rev Inst Med Trop Sao Paulo 1962; 4: 389-396.
  • 21 Araújo S.M., Chiari E. Trypanosoma cruzi infection in offspring born to chagasic C3H/He mice. Mem Inst Oswaldo Cruz 1996; 91 (02) 211-216.
  • 22 Pupulin A.R.T., Marques-Araujo S., Toledo M.J. et al. Canova medication modifies parasitological parameters in mice infected with Trypanosoma cruzi . Exp Parasitol 2010; 126 (04) 435-440.
  • 23 Chorilli M., Michelin D.C., Salgado H.R.N. Animais de laboratório: o camundongo. Rev Ciênc Farm Básica apl 2007; 28 (01) 11-23.
  • 24 Takeoka Y., Chen S.Y., Yago H. et al. The murine thymic microenvironment: changes with age. Int Arch Allergy Immunol 1996; 111 (01) 5-12.
  • 25 Gruver A.L., Hudson L.L., Sempowski G.D. Immunosenescence of ageing. J Pathol 2007; 211 (02) 144-156.
  • 26 Jenkinson W.E., Bacon A., White A.J., Anderson G., Jenkinson E.J. An epithelial progenitor pool regulates thymus growth. J Immunol 2008; 181 (09) 6101-6108.
  • 27 Dos Reis G.A., Ribeiro-Gomes F.L., Guillermo L.V., Lopes M.F. Cross-talk between apoptosis and cytokines in the regulation of parasitic infection. Cytokine Growth Factor Rev 2007; 18 1–2 97-105.
  • 28 Miranda M.A., Lopes R.A., Abrahao A.A.C., Albuquerque S., Ribeiro R.D., Sala M.A. Histometria de órgãos fetais na infecção congênita pela cepa Colombiana de Trypanosoma cruzi . Revista Científica da Universidade de Franca (SP) 2007; 7: 1-3.
  • 29 Alexander W.S. Citokines in hemapoesis. Int Rev Immunol 1998; 16 5–6 651-682.
  • 30 Figueiredo R.C. Efeitos da grandisina sobre o sistema hematopoético. Dissertação, programa de Pós graduação em Ciências Biológicas da Universidade Estadual de Maringá. 2006
  • 31 IOC - http://www.icb.usp.br/mol/12-43-linfoides-baco-17.html.
  • 32 Lenzi H.L., Lenzi J.Á., Rosman F.C., Pelajo-Machado M., Mota E.M., Panasco M.S. et al. Extramedullary hematopoiesis in murine Schistosomiasis mansoni . Memórias do Instituto Oswaldo Cruz [online] 1995; 90 (02) 169-177.
  • 33 Abreu-Silva A.L., Calabrese K.S., Cupolilo S.M., Cardoso F.O., Souza C.S., Gonçalves da Costa S.C. Histopathological studies of visceralized Leishmania (Leishmania) amazonensis in mice experimentally infected. Vet Parasitol 2004; 121 3–4 179-187 http://www.ncbi.nlm.nih.gov/pubmed/15135858 2004.
  • 34 Umekita L.F., Mota I. Role of platelets in the in vivo removal of T. cruzi from circulation. Braz J Med Biol Res 1990; 23 6–7 593-596.
  • 35 Lira-Salazar G., Marines-Montiel E., Torres-Monzon J., Hernandez-Hernandez F., Salas-Benito J.S. Effects of homeopathic medications Eupatorium perfoliatum and Arsenicum album on parasitemia of Plasmodium berghei infected mice. Homeopathy 2006; 95 (04) 223-228.
  • 36 Gupta S., Dhiman M., Wen J., Garg N.J. ROS Signalling of Inflammatory Cytokines During Trypanosoma cruzi Infection. Adv Parasitol 2011; 76: 153-170.
  • 37 Waghabi M.C., Keramidas M., Feige J.J., Araujo-Jorge T.C., Bailly S. Activation of transforming growth factor by Trypanosoma cruzi . Cell Microbiol 2005; 7 (04) 511-517.
  • 38 Borges M., Cordeiro-Da-Silva A., Sereno D., Ouaissi A. Peptide-based analysis of the amino acid sequence important to the immunoregulatory function of Trypanosoma cruzi Tc52 virulence factor. Immunology 2003; 109 (01) 147-155.
  • 39 Pereira W.K., Lonardoni M.V., Grespan R., Caparroz-Assef S.M., Cuman R.K., Bersani-Armado C.A. Immunomodulatory effect of Canova medication on experimental Leishmania amazonensis infection. J Infect 2005; 51 (02) 157-164.
  • 40 Pedalino C.M.P., Perazzo F.F., Carvalho J.C.T., Martinho K.S., Masoco C. de O., Bonamin L.V. Effect of Atropa belladonna and Echincea angustifólia in homeopathic diluction on experimental peritonitis. Homeopathy 2004; 93: 193-198.
  • 41 Pedalino CMV. Medicamentos Homeopáticos em Acordes de Potência. Artigo Original publicado na revista Cultura Homeopática Vol. 16, jul-ago-set-, pg.18–21.
  • 42 Jonas W.B., Dilnner D.K. Protection of mice from tularemia infection with ultra-low, serial agitated dilution prepared from Franciscella tularensis infected tissue. J Sci Explor 2000; 14: 35-52.
  • 43 Bastide M., Lagache A., Lemaire-Misonne C. Le paradigme des signifiants: sche‘me d’information applicable a‘ l’Immunologie et a l’Homéopathie. Rev Int Sistémique 1995; 9: 237-249.
  • 44 Heine H., Schmolz M. Immunoregulation via ‘bystander suppression’ needs minute amounts of substances a basis for homeopathic therapy?. Med Hyphotheses 2000; 54: 392-393.
  • 45 Ouma J.H., Fulford A.J., Kariuki H.C. et al. The development of schistosomiasis mansoni in animmunologically naive immigrant population in Masongaleni, Kenya. Parasitology 1998; 117 (02) 123-132.
  • 46 Andrade S.G. Apoptose e sua importância no curso da infecção pelo Trypanosoma cruzi . Rev Patol Trop 2003; 32 (02) 163-173.
  • 47 Francisco A.F. Efeito do tratamento com benznidaxol sobre o curso da infecção pela cepa y do Trypanosoma cruzi em camundongos submetidos à alteração dos estoques de ferro pelo uso da desferrioxamina. Dissertação Programa de Pós-Graduação em Ciências Biológicas da Universidade Federal de Rio Preto; 2007.
  • 48 Taylor R.C., Cullen S.P., Martin S.J. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008; 9 (03) 231-241.